Efineptakin Alfa and Pembrolizumab for the Treatment of Recurrent Glioblastoma
Efineptakin Alfa and Pembrolizumab for the Treatment of Recurrent Glioblastoma
Active, not recruiting · NCT05465954 · Registry updated 2026-10-05Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Efineptakin Alfa and Pembrolizumab for the Treatment of Recurrent Glioblastoma | Neoplasms by Histologic Type, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, astrocytoma (excluding glioblastoma), epithelial neoplasm, glioblastoma, glioma, gliosarcoma, high grade astrocytic tumor, neoplasm, neuroepithelial neoplasm, primitive neuroectodermal tumor | Active, not recruiting | Phase 2 | 2026-10-05 | NCT05465954 |
4 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Mayo Clinic | 970 |
| Merck Sharp & Dohme LLC | 650 |
| National Cancer Institute (NCI) | 3015 |
| NeoImmuneTech | 6 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Mayo Clinic | Rochester | United States | 664 |